Drug development

DDW has expanded. The longstanding first-choice publication for the drug discovery and development community now offers more content as well as more ways for you to access it. You told us what you wanted and we listened Established in 1999, DDW is the go-to brand for the industry. Following a reader survey earlier this year, […]

By FRAME (Fund for the Replacement of Animals in Medical Experiments) CEO, Celean Camp, FRAME Alternatives Laboratory Director, Dr Andrew Bennett and FRAME Scientific Liaison Officer, Amy Beale. Animals remain the first choice for testing and research in drug discovery and development, despite scientific advances across a range of other methodologies, and some tightening of […]

The emergence of SARS-CoV-2 virus and the disease it causes, COVID-19, have fuelled significant shifts in preclinical research across the globe. Amid the worldwide health emergency created by high infection rates, rapid transmission spread and relatively high mortality rates, researchers are under pressure to understand the disease’s pathogenesis, develop and test investigational therapeutics and explore […]

What a time to be involved in drug discovery. While COVID-19 has of course created unprecedented conditions on a global scale, it has also highlighted the extent to which this sector offers depth of knowledge, skill and innovation. It is a pleasure to learn more about the market – both COVID and non-COVID – and […]

The multi-year process of drug discovery and development creates huge silos of data and information. Extracting and combining information can be a significant overhead, resulting in potential for delay and error. Iperion’s Duncan van Rijsbergen provides practical recommendations to help companies create high quality, consistent data that may be shared across systems. Pharmaceutical companies are […]

Lu Rahman looks at the drug repurposing market. How attractive a proposition is it financially?  More than ever the world is watching drug development and is aware of the time it takes to get a drug to market. The 10-15 years that this can involve is costly, so unsurprisingly, drug repurposing has become a credible […]

As the world is rocked by one of the greatest healthcare challenges in living memory, how we treat infectious diseases is becoming one of the key medical questions of our age. Hannah Randles, Health and Life Sciences Champion at Liverpool City Region’s Growth Platform explains how the region’s infectious diseases ecosystem is driving innovation in […]

How do we know the medicines we take are safe and effective from batch to batch? Medicinal products like erythropoietin and gene therapies can be very challenging to quality control. Dr Mark Lies, Global Business Manager of Capillary Electrophoresis, SCIEX describes how capillary electrophoresis is being applied to address these challenges and ensure medicinal constituents […]

By Ibis Sanchez-Serrano and Rathnam Chaguturu Mitigation of COVID-19 pandemic requires a combination of effective epidemiological policies and the discovery/development of powerful drugs against the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) that causes this disease. This article examines the major initiatives being explored at the public policy level to contain the spread of COVID-19 […]

Will the next generation of CAR-T cells be modified using base editing? By Dr Jamie Freeman Volume 21 Issue 3 – Summer 2020 Base editing is a potentially transformative technology for engineering DNA in cells that has the potential to generate knockouts or correct certain errors or mutations in the DNA for applications such as […]